Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 23, 2026 16:05 ET | Source: Abivax

Abivax Announces Full Year 2025 Financial Results and Provides Business Updates

Abivax Announces Full Year 2025 Financial Results and Provides Business Updates ABTECT Phase 3 Data Safety Monitoring Board (DSMB) meeting on March 18, 2026 found no new safety signals; the analysis...
March 23, 2026 16:05 ET | Source: Sutro Biopharma, Inc.

Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights

– Dosed three cohorts in Phase 1 trial of STRO-004, potential best-in-class Tissue Factor (TF) ADC; on track to report initial clinical data in mid-2026 – – Company announced first wholly owned...
March 23, 2026 16:01 ET | Source: Apogee Therapeutics

Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering

SAN FRANCISCO and BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential...
March 23, 2026 13:17 ET | Source: Theriva Biologics, Inc.

Theriva™ Biologics anuncia el resultado positivo de la reunión de cierre de la fase 2 con la FDA de EE. UU. sobre el diseño de un ensayo de fase 3 del VCN-01 para el adenocarcinoma ductal pancreático metastásico

– El éxito de la reunión con la FDA permite avanzar hacia el ensayo clínico de fase 3 propuesto del VCN-01 en combinación con gemcitabina/nab-paclitaxel para el tratamiento de primera línea del ACDP...
March 23, 2026 13:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics invitée à présenter lors des prochaines conférences investisseurs

Nantes, France, 23 mars 2026 – 18h00 CET – OSE Immunotherapeutics SA (ISIN : FR0012127173 ; Mnemo : OSE), une société de biotechnologie au stade clinique développant des thérapies first-in-class en...
March 23, 2026 13:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics to Present at Upcoming Investor Conferences

OSE Immunotherapeutics to Present at Upcoming Investor Conferences
March 23, 2026 12:54 ET | Source: Novonesis (Novozymes A/S)

Resolutions from the Annual General Meeting 2026

Today, the Annual General Meeting of Novonesis (Novozymes A/S) was conducted. The following resolutions were made: Approval of the audited Annual Report for 2025Approval of distribution of profit...
March 23, 2026 11:15 ET | Source: Siren Biotechnology, Inc.

Siren Biotechnology Announces FDA Clearance of Investigator-Initiated IND to Advance Phase 1 Study in Recurrent High-Grade Glioma

Siren Biotechnology Announces FDA Clearance of Investigator-Initiated IND to Advance Phase 1 Study in Recurrent High-Grade Glioma
March 23, 2026 11:00 ET | Source: Checkerspot

Checkerspot Announces Breakthrough, using Microalgae to Produce Palmitoleic Acid Oil at Scale, Opening a New Pathway to Omega-7s

Checkerspot announced the first microalgae-based production of high-yield palmitoleic acid (POA) oil with a study published in the Journal Fermentation.
March 23, 2026 09:25 ET | Source: Umoja Biopharma, Inc.

Umoja Biopharma Appoints Dr. Marcela Maus and Dr. Athena Countouriotis to Board of Directors

SEATTLE, March 23, 2026 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), a clinical-stage biotechnology company committed to delivering innovative and potentially curative immunotherapies for...